ATC Group: J07BN02 Covid-19, viral vector, non-replicating

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J07BN02 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J07 Vaccines
3 J07B Viral vaccines
4 J07BN Covid-19 vaccines
5 J07BN02

Active ingredients in J07BN02

Active Ingredient

SARS-CoV-2 Spike glycoprotein (ChAdOx1-S) is a monovalent vaccine composed of a single recombinant, replication-deficient chimpanzee adenovirus (ChAdOx1) vector encoding the S glycoprotein of SARS-CoV-2. The SARS-CoV-2 S immunogen in the vaccine is expressed in the trimeric pre-fusion conformation; the coding sequence has not been modified in order to stabilise the expressed S-protein in the pre-fusion conformation. Following administration, the S glycoprotein of SARS-CoV-2 is expressed locally stimulating neutralising antibody and cellular immune responses, which may contribute to protection to COVID-19.

Related product monographs

Document Type Information Source  
 BIMERVAX Emulsion for injection MPI, EU: SmPC European Medicines Agency (EU)
 JCOVDEN Suspension for injection MPI, EU: SmPC European Medicines Agency (EU)
 VAXZEVRIA Suspension for injection MPI, EU: SmPC European Medicines Agency (EU)
 VIDPREVTYN BETA Solution and emulsion for emulsion for injection MPI, EU: SmPC European Medicines Agency (EU)

Medicines in this ATC group

Austria (AT)

Croatia (HR)

Estonia (EE)

Finland (FI)

France (FR)

Ireland (IE)

Italy (IT)

Japan (JP)

Netherlands (NL)

New Zealand (NZ)

Romania (RO)

South Africa (ZA)

Tunisia (TN)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.